ImmunityBio (IBRX) The Citizens Life Sciences Conference 2026 summary

Strategic vision and leadership

• The company is executing a long-term vision initiated in 2010, focusing on combination immunotherapy to treat cancer, with a strong emphasis on innovation and global impact.

• Leadership is closely involved in daily operations, driving execution and maintaining a science-first approach.

• The founder’s foresight in combination therapy is now validated by current industry trends and regulatory approvals.

Platform technologies and product pipeline

• Three core platforms: fusion proteins (ANKTIVA), DNA vaccine vectors, and cellular therapies, each supporting multiple indications.

• ANKTIVA is approved in 33 countries for non-muscle invasive bladder cancer, with recent FDA submissions for expanded indications.

• DNA vaccine vectors enable delivery of large payloads, supporting cancer prevention and treatment trials.

• NK cell therapy and CAR NKs are advancing, with a world bank of natural killer cells initiative and off-the-shelf products in development.

Commercial expansion and regulatory milestones

• European operations are launching, with a focus on rapid market entry and partnerships.

• U.S. and global regulatory filings are progressing, including sBLA/BLA submissions for new indications by year-end.

• Saudi Arabia became the first to approve the lung cancer indication, with other countries expressing interest.

• Commercial teams are driving strong quarter-over-quarter growth, with plans to expand indications and geographic reach.